Investor Relations

Stocktwits

Press Release

Cytori to Introduce Next-Generation Celution® Technology

Jun 01, 2017

SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), today announced plans to introduce its next-generation Celution® technology.  The technology is available for pre-orders effective June 1st, 2017 with first product shipments anticipated to begin in Q3.

The next-generation Celution® technology incorporates new hardware and enhanced software that substantially improves performance and maintains compliance with evolving global medical device and cell therapy standards. Cytori will offer the new technology through chargeable upgrades to its existing global Celution® user base (where available) and as a standard feature set for Celution® Systems purchased by new customers.

“Cytori continues to evolve its technology platforms as it simultaneously advances its clinical programs,” said John Harris, Vice President and General Manager of Cell Therapy.  “This new technology, partially supported through our BARDA contract, will be the cornerstone of our U.S. RELIEF clinical trial for thermal burn injuries and potential U.S. FDA PMA submission for Habeo™ Cell Therapy for scleroderma-associated hand dysfunction.”

This next-generation technology builds on nearly a decade of market experience, thousands of single-use procedure sets sold, numerous clinical trials and our most recent research and development activities.

“This announcement marks the most significant new evolution of our cell therapy technology in years,” said Russ Havranek, Vice President, Global Marketing at Cytori.  “This enhanced product offering should immediately resonate with our current installed base in a variety of countries and potential new customers interested in clinical cell therapy for reconstructive, aesthetic and orthopedic conditions.” 

About Cytori Therapeutics

Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions.  Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.  As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products.  Cytori Nanomedicine™ is developing liposome encapsulated therapies for regenerative medicine and oncologic indications.  For more information, visit www.cytori.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position.  Such statements, including, but not limited to, statements regarding timing for anticipated availability of Cytori’s next generation Celution® System, anticipated use of Cytori’s next generation Celution® System for Cytori’s U.S. RELIEF clinical trial for thermal burn injuries and potential U.S. FDA PMA submission for Habeo Cell Therapy, and Cytori’s plans to use its next generation Celution® System to expand its customer base and customer access to Cytori Cell Therapy, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include: risks in development, manufacture and commercial launch of Cytori’s next generation Celution® System; risks in the conduct of clinical trials, including Cytori’s RELIEF and STAR trials; risks associated with potential benefits of our Cytori’s next generation Celution® System and related products; risks in the collection and results of clinical data; risks associated with development of our clinical pipeline; final clinical outcomes; regulatory risks and uncertainties; risks related to dependence on third party performance; and other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q.  Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this communication.

Cytori Therapeutics, Inc.

Tiago Girao, 1-858-458-0900

ir@cytori.com
Source: Cytori Therapeutics

Source: Cytori Therapeutics